MEG 21 with Supplamine Overview

  • Founded
  • 1997
  • Status
  • Private
  • Employees
  • 2
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $458K
Latest Deal Amount
  • Investors
  • 6

MEG 21 with Supplamine General Information


Developer of skincare products designed to treat aging skin. The company's products are made with proprietary small molecule drugs that inhibit a novel enzymatic pathway and causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines, enabling users to use clinically validated and elegant cosmetic products

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Personal Products
Other Industries
Other Pharmaceuticals and Biotechnology
Specialty Retail
Primary Office
  • 261 Old York Road
  • Suite 427
  • Jenkintown, PA 19046
  • United States
+1 (877) 000-0000

MEG 21 with Supplamine Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MEG 21 with Supplamine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 30-Aug-2018 $458K 000.00 Completed Generating Revenue
9. Later Stage VC 13-Jun-2018 00000 000.00 Completed Generating Revenue
8. Later Stage VC 00.00 000.00 Completed Generating Revenue
7. Seed Round 03-Feb-2016 00.00 Completed Generating Revenue
6. Grant 27-Jul-2010 00.00 Completed Generating Revenue
5. Angel (individual) 27-Jul-2010 00000 00.00 Completed Generating Revenue
4. Corporate 19-Jun-2006 00.00 00.00 Completed Generating Revenue
3. Seed Round 12-Oct-1998 00000 00000 Completed Generating Revenue
2. Grant 01-Jan-1997 $100K Completed Startup
1. Joint Venture 01-Jan-1997 Completed Startup
To view MEG 21 with Supplamine’s complete valuation and funding history, request access »

MEG 21 with Supplamine Executive Team (5)

Name Title Board Seat Contact Info
Annette Tobia Ph.D Co-Founder, President, Chief Executive Officer and Board Member
Kevin Kimmel Director, Corporate Secretary and Treasurer
Frank Kappler Ph.D Co-Founder and Scientist
You’re viewing 3 of 5 executive team members. Get the full list »

MEG 21 with Supplamine Board Members (2)

Name Representing Role Since
Annette Tobia Ph.D MEG 21 with Supplamine Co-Founder, President, Chief Executive Officer and Board Member 000 0000
David Smith Self Executive Chairman and Board Member 000 0000
To view MEG 21 with Supplamine’s complete board members history, request access »

MEG 21 with Supplamine Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MEG 21 with Supplamine Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government Minority 000 0000 000000 0
Rohto Pharmaceuticals Corporation Minority 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Fox Chase Cancer Center Corporation Majority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »